Would you enjoy helping to move the pharmaceutical industry forward by facilitating the communication of scientific data and the sharing of knowledge among medical experts all over the world? Does interacting with leading Global Medical Doctors and Scientists on new innovative portfolio interest you? If yes join us on an exciting journey where we will establish our presence in NASH and build a pipeline that goes beyond the treatment of metabolic diseases. In Other Serious Chronic Diseases (OSCD), we aim to create a strong presence by building a competitive pipeline and scientific leadership. Our focus will be on non-alcoholic steatohepatitis (NASH) and New Therapy Areas such as chronic kidney disease (CKD), cardiovascular (CVD), inflammation and Alzheimer’s disease. Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs over 43,000 people in80 countries, and markets its products in more than 170 countries.
의료·간호·보건·복지>약무·제약>제약연구개발
